TP53BP1 and ovarian carcinoma: However, in breast and ovarian cancer cells with BRCA1 deficiency, 53BP1 signaling in the S/G2 phases is no longer inhibited, and RIF1 and PTIP translocate to DNA break sites via binding to phosphorylated 53BP1 to protect DNA ends from processing.